

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jenscare Scientific Co., Ltd.**  
**寧波健世科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 9877)**

**VOLUNTARY ANNOUNCEMENT**

**SIMULOCK SUCCESSFULLY COMPLETES  
IMPLANTATION SURGERY  
FOR THE FIRST CONFIRMATORY CLINICAL TRIAL**

This announcement is made by Jenscare Scientific Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development of the Group.

The board (“**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that the confirmatory clinical trial for the left atrial appendage occluder system (SimuLock) developed by Ningbo Diochange Medical Technology Co., Ltd. (寧波迪創醫療科技有限公司) (“**Diochange Medical**”), a wholly-owned subsidiary of the Company, has enrolled its first patient recently and the first implant has been successfully completed in Zhongshan Hospital affiliated to Fudan University (復旦大學附屬中山醫院). The results of such confirmatory clinical trial will be included in the registration application to be submitted by Diochange Medical to the National Medical Products Administration (國家藥品監督管理局) in the future.

SimuLock’s bionics anchoring structure and modularly assembled design based on needs can achieve safe anchoring and reduce safety risks, which can cover extensive patients with atrial fibrillation featuring significant differences in anatomical structure of the left atrial appendage. The adoption of three-dimensional sealing and controllable differential endothelial coating significantly lowers tissue irritation and prevents thromboembolism.

The Board is looking forward to the early completion of the clinical research of SimuLock, which will continue to leverage its advantages in research and development, clinical as well as manufacturing aspects, so as to bring safe and effective products to more patients.

**Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** There is no assurance that the Company will ultimately develop, market and/or commercialize SimuLock successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**Jenscare Scientific Co., Ltd.**  
**Mr. LV Shiwen**  
*Chairman and Executive Director*

Hong Kong, November 13, 2023

*As at the date of this announcement, the executive Directors are Mr. LV Shiwen and Mr. PAN Fei; the non-executive Directors are Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.*